Page last updated: 2024-08-24

valsartan and Diabetes Mellitus, Adult-Onset

valsartan has been researched along with Diabetes Mellitus, Adult-Onset in 137 studies

Research

Studies (137)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.73)	18.2507
2000's	59 (43.07)	29.6817
2010's	58 (42.34)	24.3611
2020's	19 (13.87)	2.80

Authors

Authors	Studies
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A	1
Cai, L; Cao, Z; Guo, Q; Huang, Q; Li, W; Liu, X; Zeng, R	1
Nolan, T	1
Brown, NJ; Garner, EM; Hubers, SA; Kerman, SJ; Mashayekhi, M; Nian, H; Ramirez Bustamante, CE; Shibao, CA; Wilson, JR	1
Kozak, PM; Stacey, RB; Upadhya, B; Vasan, RS	1
Bojsen-Møller, KN; Deacon, CF; Gluud, LL; Goetze, JP; Gustafsson, F; Hansen, LH; Holst, JJ; Kjeldsen, S; Madsbad, S; Martinussen, C; Møller, A; Plomgaard, P; Rashu, EB; Richter, MM; Wewer Albrechtsen, NJ	1
Barrow, BM; Castillo, JJ; Cronic, L; Esser, N; Hackney, DJ; Hogan, MF; Hull, RL; Mongovin, SM; Schmidt, C; Templin, AT; Zraika, S	1
Dodd, JD; Fox, R; Gallagher, J; Ledwidge, M; McDonald, K; McVeigh, N; Murphy, DJ; Ryan, F; Shorten, E; Sweeney, C; Watson, C; Zhou, S	1
Su, F; Xia, Q	1
Akai, H; Munakata, Y; Numahata, T; Sawada, S; Tanji, Y; Watanabe, T	1
Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H	1
Pandya, A; Spahillari, A; Yan, BW	1
Imanishi, M; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Rafiq, K; Rahman, A; Sherajee, SJ	1
Califf, RM; Gray, AM; Holman, RR; Leal, J; Li, Y; Patel, R; Reed, SD; Rivero-Arias, O; Schulman, KA	1
Bosso, G; Botta, A; Carbone, V; Carella, G; Cittadini, A; De Luca, M; Del Buono, A; Di Giovanni, G; Fimiani, B; Guardasole, V; Guarnaccia, F; Lapice, E; Martedì, E; Memoli, G; Oliva, D; Oliviero, U; Romano, G; Valvano, A; Zito, GB	1
Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Khan, MS; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH	1
Ferreira, JP; McCausland, FR; Packer, M; Patel, RB; Rossignol, P; Shah, SJ; Solomon, SD; Stockbridge, N; Ter Maaten, JM; Thompson, A; Vaduganathan, M; Zannad, F	1
Aparicio, MC; Belviso, A; Bossi, AC; Carrara, F; Cortinovis, M; De Cosmo, S; Gaspari, F; Iliev, IP; Mangili, R; Martinetti, D; Parvanova, A; Peracchi, T; Perna, A; Prandini, S; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Tonolo, G; Trevisan, R; Trillini, M	1
Esser, N; Paquot, N	1
Moon, JS; Won, KC	1
Ahn, YB; Choi, SH; Han, SJ; Jang, HC; Kim, DJ; Kim, HJ; Kim, HY; Kim, NH; Kim, SH; Kim, TH; Kim, YH; Ko, SH; Lee, KW; Lim, S; Seo, JA; Shin, DH	1
Störk, S	1
Coppey, LJ; Davidson, EP; Obrosov, A; Shevalye, H; Yorek, MA	1
Billings, FT; Brown, NJ; Eugster, P; Grouzmann, E; Hubers, SA; Jafarian Kerman, S; Nian, H; Shibao, CA; Wilson, JR; Yu, C	1
Bafor, EE; Bolanle, IO; Omogbai, EKI	1
Baffoni, C; Borretta, G; Feola, M; Gamarra, E; Tassone, F	1
Aparicio, MC; Aucella, F; Battaglia, G; Belviso, A; Bossi, AC; Carrara, F; Cortinovis, M; David, S; Diadei, O; Gaspari, F; Gregoric, N; Iliev, IP; Janez, A; Manunta, P; Martinetti, D; P Barlovic, D; Parvanova, A; Peraro, F; Perna, A; Pisani, A; Remuzzi, G; Riccio, E; Rota, S; Ruggenenti, P; Ruggiero, B; Satta, A; Stucchi, N; Trevisan, R; Trillini, M	1
Goldstein, BA; Holman, RR; Pagidipati, NJ; Pencina, MJ; Phelan, M; Stuart, EA	1
Cong, XD; Dai, DZ; Dai, Y; Ding, MJ; Liu, GL; Zhang, YM	1
Eckert, S; Freytag, SB; Klebs, SH; Müller, A	1
Chang, KH; Dikalova, AE; Engberding, N; Griendling, KK; Jo, H; Koga, M; Lassègue, B; Long, JS; Seidel-Rogol, B	1
Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK	1
Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G	1
Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K	1
Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G	1
Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y	1
Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K	1
Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D	1
Xu, C; Xu, J; Zhao, L	1
Ecder, T	1
Bi, X; Li, S; Ma, X; Miao, Y; Su, G; Sun, H; Zhang, W; Zhang, Y; Zhao, Y; Zhong, M	1
Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY	2
Bakris, GL; Cuadra, RH; Kupfer, S; Lloyd, E; White, WB	1
Boncelj Svetek, M; Eržen, B; Kanc, K; Šabovič, M	1
Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL	1
Anthony Schork, M; Coca, A; Girerd, X; Hua, TA; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; Macdonald, T; Mancia, G; McInnes, GT; Schmieder, RE; Viskoper, R; Weber, MA; Widimsky, J; Zanchetti, A	1
Kashiwagi, A; Maegawa, H; Sawaguchi, M; Uzu, T	2
Cheng, Q; de Gasparo, M; Law, PK; Leung, PS	1
Crikelair, N; Lastra, G; Levy, DG; Rocha, R; Seifu, Y; Sowers, JR	1
Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y	1
Hirose, H; Itoh, H; Komiya, N; Saisho, Y; Saito, I	1
Belousov, DIu; Belousov, IuB; Shestakova, MV	1
Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH	1
Araki, SI; Haneda, M; Isshiki, K; Kanasaki, M; Kashiwagi, A; Koya, D; Kume, S; Sakaguchi, M; Sugiomoto, T; Uzu, T; Yokomaku, Y	1
Brennan, AM; Chan, JL; Danias, PG; Khaodhiar, L; Lima, C; Manning, WJ; Mantzoros, CS; Veves, A	1
Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C	1
Braga, MF; Leiter, LA	1
Hollenberg, NK; Meng, X; Parving, HH; Remuzzi, G; Viberti, G; Weir, MR; Zappe, DH	1
Hotta, H; Ishikawa, S; Itoh, T; Kim, SJ; Kuno, A; Maeda, T; Miki, T; Miura, T; Satoh, T; Shimamoto, K; Tanno, M; Terashima, Y; Togashi, N; Yano, T	1
Bailey, J; Black, HR; Samuel, R; Zappe, D	1
Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B	1
Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R	1
Nathan, DM	1
Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J	2
Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E	1
Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E	1
Blanco-Colio, LM; Carrero, JJ; Celik, T; Egido, J; Eyileten, T; Martín-Ventura, JL; Moreno, JA; Saglam, M; Sonmez, A; Yaman, H; Yenicesu, M; Yilmaz, MI	1
Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H	1
Scheen, AJ	1
Dörffel, Y; Kappert, K; Kintscher, U; Kümmel, A; Martus, P; Marx, N; Schimkus, J; Schneider, A; Scholze, J; Stoppelhaar, M; Unger, T; Walcher, D; Winkler, R	1
Biro, S; Ikeda, Y; Kono, S; Otonari, T; Saikawa, T; Sasaki, J	1
Luan, FL	1
Higashi, K; Hiroo, K; Kushiyama, T; Oda, T; Yamamoto, K	1
Dejima, T; Fujikawa, T; Haku, S; Kanaoka, T; Kondoh, S; Konno, Y; Maeda, A; Mitsuhashi, H; Mizushima, S; Moriya, T; Ogawa, N; Ohsawa, M; Okano, Y; Ozawa, M; Suzuki, D; Tamura, K; Tanaka, K; Toyoda, M; Umemura, S; Umezono, T; Wakui, H; Yamakawa, T; Yanagi, M	1
Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Lim, DS; Park, JH	1
Vértes, A	1
Hollenberg, NK; Meng, X; Parving, HH; Remuzzi, G; Weir, MR; Zappe, DH	1
Blaak, EE; Diamant, M; Goossens, GH; Ijzerman, RG; Moors, CC; Serné, EH; van der Zijl, NJ	1
Peng, XD; Yang, ZH	1
Ichimiya, S; Ikeda, N; Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Ohno, M; Shintani, S; Sone, T; Watarai, M; Yamashita, K	1
Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC	1
Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z	1
Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A	1
Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M	1
Nabbi, R; Riess, ML; Woehlck, HJ	1
Fan, YY; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Mori, H; Nakano, D; Nishiyama, A	1
Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Masada, M; Morikawa, T; Nishiyama, A; Okada, N; Shirahashi, N; Wilcox, CS	1
Volpe, M	1
Alessi, T; Bakris, GL; Oparil, S; Purkayastha, D; Sowers, JR; Yadao, AM	1
Aizawa, Y; Ikarashi, T; Kaneko, S; Nakagawa, O; Souda, S; Suzuki, K	1
Viberti, G; Wheeldon, NM	1
Borovkov, NN; Sidorova, NV	1
Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV	1
Cui, TX; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Okumura, M; Shiuchi, T; Wu, L	1
Aizawa, Y; Kamimura, T; Kato, K; Soda, S; Suzuki, K	1
Takeuchi, M; Yamagishi, S	1
Eguchi, Y; Miura, Y; Oiso, Y; Ozaki, N; Taguchi, S; Tsunekawa, S; Yamamoto, N	1
Cimpanelli, M; Crespi, C; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Riganti, G; Schizzarotto, A; Simoni, C; Venco, A	1
Fukuhara, S; Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A	1
Inoguchi, T; Kobayashi, K; Maeda, Y; Nakayama, M; Nawata, H; Sasaki, S; Sawada, F; Sonoda, N; Sonta, T; Sumimoto, H; Tsubouchi, H	1
Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM	1
Heljić, B; Velija-Asimi, Z	1
Hausberg, M; Hohage, H; Kosch, M	1
Anabitarte, A; Caballero, A; Novoa Novoa, J; Palop, L; Plaza, C; Rodríguez Esparragón, F; Rodríguez Pérez, JC	1
Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C	1
Dudley, K; Ferran, C; Ganda, O; Hubbard, M; Khaodhiar, L; Lima, C; Scali, S; Shrikhande, G; Veves, A	1
Ishikawa, H; Katayama, K; Koyabu, S; Murata, T; Nakano, T; Nomura, S	1
Endo, K; Koide, N; Miyashita, Y; Murano, T; Ohira, M; Oyama, T; Saiki, A; Shirai, K	1
Adams, F; Boschmann, M; Engeli, S; Franke, G; Jordan, J; Klaua, S; Kreuzberg, U; Luft, FC; Scholze, J; Sharma, AM; Weidinger, G	1
Hirose, H; Komiya, N; Saisho, Y	1
Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F	1
De Ciuceis, C; Endemann, DH; Ko, EA; Pu, Q; Savoia, C; Schiffrin, EL; Touyz, RM	1
Coca, A; Ekman, S; Girerd, X; Hua, T; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; MacDonald, TM; Mancia, G; McInnes, GT; Schmieder, RE; Schork, MA; Stolt, P; Viskoper, R; Weber, MA; Widimský, J; Zanchetti, A	1
Savoia, C; Schiffrin, EL; Touyz, RM; Volpe, M	1
Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV	1
Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D	1
Itoh, Y; Mori, Y; Tajima, N	1
Daley, WL; Hollenberg, NK; Kandra, A; Parving, HH; Remuzzi, G; Ritter, S; Rocha, R; Viberti, G; Zelenkofske, S	1
Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM	1
Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T	1
Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y	1
Allemann, Y; Barbier, M; Ferber, P; Fraile, B; Izzo, JL; Lambert, M	1
Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A	1
Botha, J; DeAngelis, L; Ferber, P; Kandra, A; Karalliedde, J; Mirenda, V; Smith, A; Viberti, G	1
Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C	1
Botteri, F; Cheung, R; Huff, MW; Lewanczuk, RZ; Muirhead, N; Oddou-Stock, P; Pecher, E; Rodger, NW	1
Coats, AJ	1
Shimoni, Y	1
Dunseath, G; Luzio, SD; Owens, DR	1

Reviews

10 review(s) available for valsartan and Diabetes Mellitus, Adult-Onset

Article	Year
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current hypertension reports, 2022, Volume: 24, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left	2022
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 03-02, Volume: 143, Issue:9 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Valsartan	2021
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors. Blood pressure, 2013, Volume: 22 Suppl 1 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Obesity, Abdominal; Risk Factors; Tetrazoles; Valine; Valsartan	2013
Renal and metabolic effects of valsartan. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2014, Volume: 14 Suppl 2 Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Humans; Protective Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan	2014
Role of renin-angiotensin system blockade in patients with diabetes mellitus. The American journal of cardiology, 2009, Sep-15, Volume: 104, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function	2009
Valsartan: more than a decade of experience. Drugs, 2009, Volume: 69, Issue:17 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan	2009
Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva cardioangiologica, 2009, Volume: 57, Issue:6 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2009
Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:8 Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan	2012
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. Kardiologiia, 2003, Volume: 43, Issue:2 Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2003
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL. International journal of cardiology, 2001, Volume: 79, Issue:2-3 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Valine; Valsartan	2001

Trials

66 trial(s) available for valsartan and Diabetes Mellitus, Adult-Onset

Article	Year
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension (Dallas, Tex. : 1979), 2022, Volume: 79, Issue:4 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Aprepitant; Blood Pressure; Cardiovascular Agents; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Humans; Norepinephrine; Ramipril; Renin-Angiotensin System; Sitagliptin Phosphate; Valsartan	2022
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:10 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Neprilysin; Sitagliptin Phosphate; Tetrazoles; Valsartan	2022
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial. JAMA cardiology, 2023, 04-01, Volume: 8, Issue:4 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Female; Heart Atria; Heart Failure; Humans; Hypertension; Male; Natriuretic Peptide, Brain; Neprilysin; Stroke Volume; Tetrazoles; Valsartan	2023
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes care, 2020, Volume: 43, Issue:10 Topics: Adult; Age of Onset; Aged; Benchmarking; Cardiometabolic Risk Factors; Cardiovascular Diseases; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Mortality; Prediabetic State; Primary Prevention; Quality of Life; Quality-Adjusted Life Years; United Kingdom; United States; Valsartan	2020
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS medicine, 2021, Volume: 18, Issue:7 Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Valsartan	2021
Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. The Korean journal of internal medicine, 2017, Volume: 32, Issue:3 Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Valsartan	2017
DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition. Hypertension (Dallas, Tex. : 1979), 2018, Volume: 72, Issue:3 Topics: Adult; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Female; Humans; Male; Middle Aged; Neuropeptide Y; Renin-Angiotensin System; Sitagliptin Phosphate; Valsartan; Vasoconstriction; Young Adult	2018
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:5 Topics: Adult; Aged; Benzazepines; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Italy; Kidney Function Tests; Male; Middle Aged; Slovenia; Treatment Outcome; Valsartan	2019
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes, 2013, Volume: 62, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:11 Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Female; Glucuronidase; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Klotho Proteins; London; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Renin-Angiotensin System; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2013
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. The American journal of cardiology, 2013, Dec-01, Volume: 112, Issue:11 Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. American heart journal, 2013, Volume: 166, Issue:5 Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan	2013
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. Disease markers, 2015, Volume: 2015 Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Male; Middle Aged; Valsartan	2015
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. Journal of hypertension, 2016, Volume: 34, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Imidazoles; Male; Middle Aged; Oxadiazoles; Prediabetic State; Tetrazoles; Valsartan	2016
Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan. Journal of diabetes and its complications, 2017, Volume: 31, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pulse Wave Analysis; Ultrasonography; Valsartan; Vascular Stiffness; Vasodilation	2017
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood pressure, 2008, Volume: 17, Issue:3 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Humans; Hypertension; Middle Aged; Multivariate Analysis; Regression Analysis; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2008
Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:6 Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan	2008
Initial combination therapy compared with monotherapy in diabetic hypertensive patients. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:9 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan	2008
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes research and clinical practice, 2009, Volume: 83, Issue:1 Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan	2009
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. Kardiologiia, 2008, Volume: 48, Issue:12 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypertension; Irbesartan; Kidney Diseases; Tetrazoles; Valine; Valsartan	2008
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:12 Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prediabetic State; Risk Factors; Tetrazoles; Valine; Valsartan; Young Adult	2008
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clinical and experimental nephrology, 2009, Volume: 13, Issue:4 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Japan; Losartan; Male; Middle Aged; Prospective Studies; Sodium; Sodium, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan	2009
Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aorta; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Young Adult	2009
Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. Journal of hypertension, 2010, Volume: 28, Issue:1 Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult	2010
Effect of nateglinide on the incidence of diabetes and cardiovascular events. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan	2010
Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan	2010
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:7 Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Protein; Calcium Channel Blockers; Chi-Square Distribution; Cytokine TWEAK; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Serum Amyloid P-Component; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factors; Turkey; Valine; Valsartan; Vasodilation	2010
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. European journal of internal medicine, 2010, Volume: 21, Issue:3 Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2010
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide]. Revue medicale de Liege, 2010, Volume: 65, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan	2010
Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes research and clinical practice, 2010, Volume: 89, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Interleukin-6; Lipids; Male; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan	2010
Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1). Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:9 Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2010
[The Shiga Microalbuminuria Reduction Trial]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68 Suppl 9 Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Middle Aged; Prospective Studies; Rats; Tetrazoles; Valine; Valsartan	2010
Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. Heart (British Cardiac Society), 2011, Volume: 97, Issue:17 Topics: Adiponectin; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Stenosis; Diabetes Mellitus, Type 2; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Neointima; Prospective Studies; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography, Interventional; Valine; Valsartan	2011
Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. Journal of hypertension, 2011, Volume: 29, Issue:10 Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2011
Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism. Journal of hypertension, 2011, Volume: 29, Issue:10 Topics: Adipokines; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Capillaries; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation Mediators; Insulin Resistance; Male; Microvessels; Middle Aged; Tetrazoles; Valine; Valsartan	2011
Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension (Dallas, Tex. : 1979), 2012, Volume: 59, Issue:3 Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypertension; Japan; Male; Middle Aged; Morbidity; Prospective Studies; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan	2012
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Advances in therapy, 2012, Volume: 29, Issue:2 Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin	2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:8 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Ramipril; Tetrazoles; Valine; Valsartan	2012
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando Clinical therapeutics, 2012, Volume: 34, Issue:8 Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Prospective Studies; Taiwan; Tetrazoles; Time Factors; Treatment Outcome; Uric Acid; Valine; Valsartan	2012
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2013, Volume: 14, Issue:1 Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressure; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Humans; Kidney; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Receptors, Angiotensin; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan	2013
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. Journal of clinical hypertension (Greenwich, Conn.), 2013, Volume: 15, Issue:2 Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Comorbidity; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes research and clinical practice, 2002, Volume: 57, Issue:3 Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2002
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation, 2002, Aug-06, Volume: 106, Issue:6 Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2002
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes care, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan	2005
Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thrombosis research, 2006, Volume: 117, Issue:4 Topics: Aged; Biomarkers; Cytokines; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Hypertension; Male; Middle Aged; Monocytes; Tetrazoles; Valine; Valsartan	2006
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clinical therapeutics, 2005, Volume: 27, Issue:5 Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan	2005
The effects of valsartan on lipid profile in normotensive type 2 diabetic patients. Medicinski arhiv, 2005, Volume: 59, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Lipids; Middle Aged; Tetrazoles; Valine; Valsartan	2005
[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25, Issue:5 Topics: Adult; Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan	2005
Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. Journal of vascular surgery, 2006, Volume: 43, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biopsy, Needle; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Microcirculation; Middle Aged; Probability; Prospective Studies; Reference Values; Regional Blood Flow; Risk Assessment; Severity of Illness Index; Skin; Tetrazoles; Treatment Outcome; Valine; Valsartan	2006
Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney international, 2006, Volume: 70, Issue:1 Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan	2006
The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes research and clinical practice, 2006, Volume: 74, Issue:3 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2006
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:5 Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Glycerol; Humans; Hypertension; Insulin; Kinetics; Lactic Acid; Lipids; Male; Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Tetrazoles; Valine; Valsartan	2006
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:2 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biopsy; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Organ Culture Techniques; Subcutaneous Tissue; Systole; Tetrazoles; Time; Treatment Outcome; Valine; Valsartan	2006
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of hypertension, 2006, Volume: 24, Issue:7 Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Risk Factors; Tetrazoles; Valine; Valsartan	2006
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vasodilation	2007
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American journal of hypertension, 2006, Volume: 19, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2006
Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes care, 2007, Volume: 30, Issue:6 Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2007
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. Journal of hypertension, 2007, Volume: 25, Issue:9 Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2007
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovascular diabetology, 2007, Oct-02, Volume: 6 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Obesity; Placebos; Single-Blind Method; Systole; Telmisartan; Tetrazoles; Valine; Valsartan	2007
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. American journal of hypertension, 2007, Volume: 20, Issue:12 Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2007
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:3 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Retreatment; Tetrazoles; Valine; Valsartan	2008
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:3 Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension; Male; Middle Aged; Propafenone; Prospective Studies; Secondary Prevention; Tetrazoles; Valine; Valsartan	2008
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan	2008
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:10 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan	2008
The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. International journal of clinical practice, 1999, Volume: 53, Issue:8 Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Tetrazoles; Valine; Valsartan	1999
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2002, Volume: 34, Issue:5 Topics: Adolescent; Adult; Antihypertensive Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Tetrazoles; Valine; Valsartan	2002

Other Studies

61 other study(ies) available for valsartan and Diabetes Mellitus, Adult-Onset

Article	Year
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:3 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Valsartan alleviates the blood-brain barrier dysfunction in db/db diabetic mice. Bioengineered, 2021, Volume: 12, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood-Brain Barrier; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells; Inflammation; Male; Mice; Valsartan; Vascular Diseases	2021
Tom Nolan's research reviews-26 November 2021. BMJ (Clinical research ed.), 2021, 11-26, Volume: 375 Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Cats; COVID-19; COVID-19 Serotherapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dogs; Drug Combinations; Gastric Inhibitory Polypeptide; Heart Sounds; History, 20th Century; Humans; Hypertension; Immunization, Passive; Incretins; Insulin Glargine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; SARS-CoV-2; Thiazides; Valsartan	2021
Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice. Frontiers in endocrinology, 2022, Volume: 13 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Insulin Resistance; Insulins; Mice; Mice, Inbred C57BL; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan	2022
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:5 Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Interleukin-6; Tablets; Thioctic Acid; Valsartan	2023
Marked Increase in Urinary C-peptide Levels after Treatment with Sacubitril/Valsartan in Patients with Type 2 Diabetes Mellitus and Hypertension. Internal medicine (Tokyo, Japan), 2023, Dec-01, Volume: 62, Issue:23 Topics: Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan	2023
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, Oct-31, Volume: 38, Issue:11 Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mice; Natriuretic Peptides; Renal Plasma Flow; Valsartan	2023
Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States. Circulation. Cardiovascular quality and outcomes, 2023, Volume: 16, Issue:6 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left	2023
The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats. Journal of pharmacological sciences, 2020, Volume: 142, Issue:3 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Proteinuria; Rats; Rats, Inbred OLETF; Tetrazoles; Valsartan	2020
Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. Internal and emergency medicine, 2021, Volume: 16, Issue:4 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Italy; Male; Valsartan	2021
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC. Heart failure, 2021, Volume: 9, Issue:2 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Remodeling	2021
[Potential role of sacubitril/valsartan combination in type 2 diabetes]. Revue medicale suisse, 2021, Aug-25, Volume: 17, Issue:747 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Neprilysin; Valsartan	2021
Oxidative stress: link between hypertension and diabetes. The Korean journal of internal medicine, 2017, Volume: 32, Issue:3 Topics: Amlodipine; Diabetes Mellitus, Type 2; Humans; Hypertension; Oxidative Stress; Valsartan	2017
Renal effects of sacubitril/valsartan in patients with diabetes. The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:7 Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan	2018
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone. Diabetes, 2018, Volume: 67, Issue:8 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Diet, High-Fat; Disease Progression; Drug Combinations; Male; Neprilysin; Neural Conduction; Neuroprotective Agents; Protease Inhibitors; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Resistance	2018
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 106 Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Drug Interactions; Glyburide; Hypoglycemic Agents; Male; Rats, Wistar; Risk Assessment; Streptozocin; Time Factors; Valsartan	2018
Reduction of Insulin Requirement After Starting Treatment With Sacubitril/Valsartan in a Patient with Diabetes Treated With Continuous Subcutaneous Insulin Infusion (CSII): A case report. Journal of diabetes science and technology, 2018, Volume: 12, Issue:6 Topics: Aminobutyrates; Biphenyl Compounds; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Humans; Infusions, Subcutaneous; Insulin; Insulin Infusion Systems; Insulin Resistance; Male; Middle Aged; Tetrazoles; Valsartan	2018
An outcome model approach to transporting a randomized controlled trial results to a target population. Journal of the American Medical Informatics Association : JAMIA, 2019, 05-01, Volume: 26, Issue:5 Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Electronic Health Records; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Machine Learning; Nateglinide; Outcome Assessment, Health Care; Prediabetic State; Randomized Controlled Trials as Topic; Translational Research, Biomedical; Valsartan	2019
Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan. European journal of pharmacology, 2013, Aug-05, Volume: 713, Issue:1-3 Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Combinations; Endoplasmic Reticulum Stress; Hypogonadism; I-kappa B Proteins; Male; Rats; Rats, Sprague-Dawley; Sexual Behavior, Animal; Streptozocin; Tetrazoles; Valine; Valsartan	2013
The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice. American journal of physiology. Heart and circulatory physiology, 2013, Sep-01, Volume: 305, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Bone Morphogenetic Proteins; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Male; Mice; Mice, Mutant Strains; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan; Vasculitis	2013
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovascular diabetology, 2013, Nov-04, Volume: 12 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan	2013
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovascular diabetology, 2013, Nov-04, Volume: 12 Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin	2013
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ (Clinical research ed.), 2013, Dec-09, Volume: 347 Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation. Cardiology, 2014, Volume: 129, Issue:3 Topics: Aged; Antihypertensive Agents; Autoantibodies; Biomarkers; Diabetes Mellitus, Type 2; Dilatation, Pathologic; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Metoprolol; Middle Aged; Predictive Value of Tests; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Risk Factors; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan	2014
Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats. Diagnostic pathology, 2015, Apr-02, Volume: 10 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, High-Fat; Fibrosis; Male; Rats, Wistar; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Streptozocin; Thrombospondin 1; Time Factors; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling	2015
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. Journal of the American Heart Association, 2017, 01-13, Volume: 6, Issue:1 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan	2017
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl] The Journal of pharmacology and experimental therapeutics, 2008, Volume: 327, Issue:3 Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Fibrosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Pyrrolidines; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan	2008
Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. International heart journal, 2008, Volume: 49, Issue:6 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adiponectin; Aged; Albuminuria; Antihypertensive Agents; Aryldialkylphosphatase; Biomarkers; C-Reactive Protein; Carotid Arteries; Diabetes Mellitus, Type 2; Dinoprost; Female; Glycation End Products, Advanced; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Tetrazoles; Valine; Valsartan	2008
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology (Carlton, Vic.), 2009, Volume: 14, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan	2009
Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circulation research, 2010, Jan-08, Volume: 106, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Diabetes Mellitus, Type 2; Enkephalin, Leucine-2-Alanine; Erythropoietin; Immunosuppressive Agents; Ischemic Preconditioning, Myocardial; Janus Kinase 2; Losartan; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred OLETF; Receptor, Angiotensin, Type 1; Receptors, Opioid, delta; Signal Transduction; Species Specificity; Tacrolimus; Tetrazoles; Up-Regulation; Valine; Valsartan	2010
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:3 Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan	2010
Navigating the choices for diabetes prevention. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan	2010
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. Journal of hypertension, 2010, Volume: 28, Issue:7 Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan	2010
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats. British journal of pharmacology, 2010, Volume: 160, Issue:1 Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure	2010
Effect of valsartan on the incidence of diabetes. The New England journal of medicine, 2010, 08-19, Volume: 363, Issue:8 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Diuretics; Humans; Hypertension; Incidence; Tetrazoles; Valine; Valsartan	2010
Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study. Clinical and experimental hypertension (New York, N.Y. : 1993), 2011, Volume: 33, Issue:4 Topics: Albuminuria; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Indoles; Kidney; Lipids; Male; Middle Aged; Pilot Projects; Prospective Studies; Regression Analysis; Tetrazoles; Valine; Valsartan	2011
[The significance of generic valsartan in the treatment of patients]. Lege artis medicinae : uj magyar orvosi hirmondo, 2011, Volume: 21, Issue:2 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Generic; Humans; Hypertension; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2011
Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus. Chinese medical journal, 2010, Volume: 123, Issue:24 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Collagen Type I; Collagen Type III; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Hydroxyproline; Insulin Resistance; Male; Myocardium; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan	2010
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Experimental diabetes research, 2012, Volume: 2012 Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Endothelial Cells; Endothelium, Vascular; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; NADPH Oxidases; Oxidative Stress; Pyrrolidines; Receptors, Glucagon; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1	2012
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. European journal of pharmacology, 2012, Jun-15, Volume: 685, Issue:1-3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan	2012
Angiotensin-receptor-blocker-induced refractory hypotension responds to methylene blue. Acta anaesthesiologica Scandinavica, 2012, Volume: 56, Issue:7 Topics: Aged; Angiotensin Receptor Antagonists; Carbazoles; Carvedilol; Citalopram; Crystalloid Solutions; Diabetes Mellitus, Type 2; Drug Resistance; Female; Gastric Bypass; Humans; Hypotension; Isotonic Solutions; Obesity, Morbid; Phenylephrine; Preoperative Care; Propanolamines; Tetrazoles; Valine; Valsartan	2012
Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. Journal of pharmacological sciences, 2012, Volume: 119, Issue:2 Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fumarates; Kidney; Male; Mice; Mice, Inbred C57BL; Renin; RNA, Messenger; Tetrazoles; Valine; Valsartan	2012
[24-hour arterial hypertension profile and heart rhythm variability in patients with arterial hypertension and NIDDM]. Klinicheskaia meditsina, 2002, Volume: 80, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Circadian Rhythm; Diabetes Mellitus, Type 2; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2002
Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Crosses, Genetic; Deoxyglucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Intake; Gene Expression Regulation; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Pyridines; Signal Transduction; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan	2004
The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients. Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Echocardiography; Female; Glycated Hemoglobin; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan	2004
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis; Tetrazoles; Valine; Valsartan	2004
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks]. Praxis, 2004, Oct-13, Volume: 93, Issue:42 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors; Valine; Valsartan	2004
[VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks]. Praxis, 2004, Oct-27, Volume: 93, Issue:44 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan	2004
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Medical hypotheses, 2005, Volume: 64, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan	2005
Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension. Journal of cardiovascular pharmacology, 2005, Volume: 45, Issue:4 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Lipids; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2005
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochemical and biophysical research communications, 2005, Jul-15, Volume: 332, Issue:4 Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Body Weight; Deoxyguanosine; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Islets of Langerhans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tetrazoles; Time Factors; Valine; Valsartan	2005
[Hypertension and diabetic nephropathy, a dangerous duo]. Medizinische Klinik (Munich, Germany : 1983), 2005, Nov-15, Volume: 100, Issue:11 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Male; Metabolic Syndrome; Ramipril; Tetrazoles; Valine; Valsartan	2005
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vascular medicine (London, England), 2005, Volume: 10 Suppl 1 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan	2005
Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes research and clinical practice, 2006, Volume: 74, Issue:2 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycosylation; Humans; Hypertension; Japan; Tetrazoles; Thiobarbituric Acid Reactive Substances; Valine; Valsartan	2006
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney international, 2006, Volume: 70, Issue:3 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex	2006
[Lowering blood pressure substantially--and the diabetes risk as well?]. MMW Fortschritte der Medizin, 2006, Jul-20, Volume: 148, Issue:29-30 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypertension; Sodium Chloride Symporter Inhibitors; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2006
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. Journal of human hypertension, 2007, Volume: 21, Issue:5 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tetrazoles; Time Factors; Treatment Outcome; United States; Valine; Valsartan	2007
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. American journal of hypertension, 2007, Volume: 20, Issue:4 Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan	2007
[Valsartan: arguments for the high dose concept]. MMW Fortschritte der Medizin, 2006, Dec-14, Volume: 148, Issue:51-52 Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Hypertension, Renal; Proteinuria; Tetrazoles; Valine; Valsartan	2006
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. American journal of hypertension, 2008, Volume: 21, Issue:2 Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan	2008
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes. The Journal of physiology, 2001, Nov-15, Volume: 537, Issue:Pt 1 Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electric Conductivity; Isoquinolines; Mutation; Potassium Channels; Quinapril; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Angiotensin, Type 2; Receptors, Cell Surface; Receptors, Leptin; Saralasin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan	2001